Tweenvest Stocks

Inozyme Pharma, Inc. (NasdaqGM: INZY)

Health Care · Biotechnology · US

$

today · 1Y

Inozyme Pharma, Inc. (NasdaqGM: INZY) operates in the Biotechnology industry within the Health Care sector.

Tweenvest scores Inozyme Pharma, Inc. across four factors: quality 26/100. Its strongest factor is quality.

INZY price history

Not enough price history to draw a chart yet.

Key figures

Market cap
Revenue (TTM)
P/E
EPS
-1.68
Dividend yield
Beta (5Y)
52-week high
$—
52-week low
$—
Avg volume (3M)
Shares outstanding
Employees
67
Next earnings

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.

Founded
2015
Listed since
Jul 24, 2020
Exchange
Nasdaq Global Market
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$468.22B$264.96+1.20%
Amgen Inc.NasdaqGS: AMGN$237.52B$441.75+0.55%
Gilead Sciences, Inc.NasdaqGS: GILD$181.18B$146.61+0.34%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$138.91B$548.05+1.44%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$83.28B$834.04+0.90%
argenx SEENXTBR: ARGX$65.85B883.80-2.02%
Moderna, Inc.NasdaqGS: MRNA$57.92B$143.00-1.43%
CSL LimitedASX: CSL$57.77BAU$168.30-1.69%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.